Physician profile

Nora Martini

Valhalla, NY

NPI 1679154801

$881.49

in general payments reported to CMS, 2019-2025

6 companies · $757 in 2025

The $757 reported for 2025 was more than what 85% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$881.49

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $285.77 2024-2025 Fasenra
Glaxosmithkline, LLC. $274.06 2025 Nucala
Novo Nordisk INC $125.00 2025 Ozempic
Siemens Medical Solutions USA, INC. $125.00 2025 Cios Spin
La Jolla Pharmaceutical Company $42.50 2025 Giapreza
Medtronic, INC. $29.16 2025 Tyrx

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Nora Martini

$881.49

in general payments reported 2019-2025

Years
2024-2025
Top company
Astrazeneca Pharmaceuticals LP
Context
The $757 reported for 2025 was more than what 85% of providers received nationally.

https://glasscript.com/doctor/11829506/nora-martini

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.